iBio, Inc. (IBIO) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-05-15. Read in-app with summaries. First-party data.
Investor Presentation View Presentation: iBio is developing a portfolio of next-generation antibodies for obesity and cardiometabolic diseases, led by the Activin E antibody IBIO-610.
| Published | Type | Document |
|---|---|---|
| 2026-05-15 | Presentation | Investor Presentation View Presentation |
| 2025-05-02 | Press release | iBio Reports Fiscal Third Quarter 2025 Financial Results |
| 2024-11-12 | Press release | iBio Reports Fiscal First Quarter 2025 Financial Results |
| 2024-09-20 | Press release | iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update |
| 2024-05-13 | Press release | iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update |
| 2022-05-12 | Press release | iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update |
| 2022-02-14 | Press release | iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update |
| 2021-11-15 | Press release | Earnings ReleaseHTML |
| 2021-09-27 | Press release | Earnings ReleaseHTML |
| 2021-05-17 | Press release | Earnings ReleaseHTML |
IBIO overview · IBIO earnings · IBIO financials · IBIO KPIs · IBIO ownership · IBIO peers · IBIO filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.